Aptamer Detection of Mycobaterium tuberculosis Mannose-Capped Lipoarabinomannan in Lesion Tissues for Tuberculosis Diagnosis
stage three lung cancer :: Article Creator Tagrisso May Improve Survival In Advanced EGFR-Mutant NSCLC Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer. For patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer, Tagrisso associated with positive outcomes. Tagrisso (osimertinib) has been found to be associated with positive outcomes, including improvements in overall survival, among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer (NSCLC). These findings, it has been posited, position Tagrisso as the new standard of care treatment for this patient population, according to findings from the international phase 3 LAURA study presented at the European Lung Cancer Congress (ELCC) 2025. "In summary, this updated overall survival analysis from the LAURA study demonstrates an improved favorable trend for overall ...